Phathom Pharmaceuticals (PHAT) News Today $8.37 +0.23 (+2.83%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up Following Insider Buying ActivityDecember 18 at 1:07 AM | americanbankingnews.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires 12,500 Shares of StockDecember 17 at 5:03 AM | insidertrades.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Insider Buying ActivityPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying ActivityDecember 16 at 10:31 AM | marketbeat.comFrank Karbe Acquires 12,500 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) Director Frank Karbe acquired 12,500 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average cost of $7.93 per share, for a total transaction of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares of the company's stock, valued at $452,010. The trade was a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.December 16 at 10:17 AM | marketbeat.comPhathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA TabletsDecember 13, 2024 | americanbankingnews.comPhathom Pharmaceuticals: Securing Long-term Exclusivity for Growth PotentialDecember 12, 2024 | markets.businessinsider.comPhathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended ExclusivityDecember 12, 2024 | markets.businessinsider.comDo You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?December 12, 2024 | msn.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday.December 12, 2024 | marketbeat.comPhathom Pharmaceuticals: The Large Drop Is, Well, UnfathomableDecember 11, 2024 | seekingalpha.comPhathom Pharmaceuticals submits Citizen Petition to FDADecember 11, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) TabletsDecember 11, 2024 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Bought by Fmr LLCFmr LLC raised its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 49,000.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,304,114 shares of the company's stock after acquiring an adDecember 10, 2024 | marketbeat.comPhathom Pharmaceuticals, Inc. Common Stock (PHAT) After-HoursDecember 9, 2024 | nasdaq.comAnalysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Kura Oncology (KURA)December 9, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Buys Shares of 439,816 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Point72 Asset Management L.P. bought a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 439,816 shares of the company's stock, valued at approximately $December 8, 2024 | marketbeat.comWasatch Advisors LP Invests $4.47 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Wasatch Advisors LP purchased a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 246,942 shares of the coDecember 1, 2024 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Sees Large Drop in Short InterestPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 14,660,000 shares, a decrease of 16.0% from the October 31st total of 17,450,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is currently 10.9 days.November 30, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.5% - Should You Sell?Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.5% - Here's What HappenedNovember 29, 2024 | marketbeat.comEagle Asset Management Inc. Increases Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Eagle Asset Management Inc. boosted its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 25.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 455,196 shares of the companNovember 25, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down - Here's WhyPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down - Should You Sell?November 22, 2024 | marketbeat.comJennison Associates LLC Grows Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Jennison Associates LLC grew its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 112.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,866,389 shares of the company's stock after purchasing an additioNovember 21, 2024 | marketbeat.comCraig-Hallum Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)November 13, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (PHAT) Receives a Buy from Stifel NicolausNovember 11, 2024 | markets.businessinsider.comPhathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9% - Here's What HappenedPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 8.9% - Time to Sell?November 8, 2024 | marketbeat.comPhathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...November 8, 2024 | finance.yahoo.comPhathom Pharmaceuticals Reports Significant Revenue GrowthNovember 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Surpasses Expectations: Strong Q3 Performance and Bullish Outlook Drive Increased Revenue Estimates and Price TargetNovember 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look ForNovember 6, 2024 | finance.yahoo.comPhathom Pharmaceuticals (PHAT) Gets a Buy from Craig-HallumNovember 4, 2024 | markets.businessinsider.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comInvestors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%November 2, 2024 | finance.yahoo.comNeedham Sticks to Their Hold Rating for Lexicon Pharmaceuticals (LXRX)October 31, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (PHAT) to Release Earnings on ThursdayPhathom Pharmaceuticals (NASDAQ:PHAT) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=640871)October 31, 2024 | marketbeat.comLow-Volume Bowel Prep Matches Standard for Inpatient ColonoscopyOctober 29, 2024 | msn.comPhathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024October 28, 2024 | globenewswire.comPhathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual MeetingOctober 27, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)October 25, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8% - What's Next?Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8% - Time to Buy?October 18, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 3.4% - What's Next?Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 3.4% - Time to Sell?October 14, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.5% - Should You Sell?Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.5% - Should You Sell?October 7, 2024 | marketbeat.comMarshall Wace LLP Invests $1.16 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Marshall Wace LLP purchased a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 112,691 shares of the company's stock, valued at approximOctober 7, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 4.8% Higher Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 4.8%October 3, 2024 | marketbeat.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)September 25, 2024 | prnewswire.comOracle Investment Management Inc. Buys Shares of 225,000 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Oracle Investment Management Inc. purchased a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 225,000 shares of tSeptember 24, 2024 | marketbeat.comEnsign Peak Advisors Inc Sells 35,172 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Ensign Peak Advisors Inc trimmed its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 1.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,244,828 sharesSeptember 23, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year High at $19.76Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year High at $19.76September 19, 2024 | marketbeat.comBuy Rating Affirmed: Phathom Pharmaceuticals’ V oquezna Shows Promising Market Penetration and Growth PotentialSeptember 14, 2024 | markets.businessinsider.com Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.730.72▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼153▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NewAmsterdam Pharma News IDEAYA Biosciences News Centessa Pharmaceuticals News Recursion Pharmaceuticals News ImmunityBio News Apogee Therapeutics News Wave Life Sciences News Mirum Pharmaceuticals News Akero Therapeutics News Amphastar Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAT Stock Alerts